Výsledky vyhledávání - "D A, van Echo"

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Autor: JP Holmes, George E. Peoples, Erika J Schneble, Guy T. Clifton, Sathibalan Ponniah, D. A. Van Echo, Elizabeth A. Mittendorf

Publikováno v: Annals of Oncology. 25:1735-1742

Background: E75 (nelipepimut-S) is a human leukocyte antigen (HLA)-A2/A3-restricted immunogenic peptide derived from the HER2 protein. We have conducted phase I/II clinical trials vaccinating breast cancer patients with nelipepimut-S and granulocyte�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64b1189509139ead7b260fdab50973dd
https://doi.org/10.1093/annonc/mdu211

Zobrazit plný text záznamu

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

Autor: D. A. Van Echo, Peter H. Wiernik, James H. Doroshow, K. Margolin, M Sznol, Frederick R. Aronson, David Parkinson, Anthony A. Rayner, Janice P. Dutcher, Jeff Abrams

Publikováno v: Journal of Clinical Oncology. 8:1650-1656

Forty-seven patients with metastatic malignant melanoma were treated with two 5-day cycles of 100,000 U/kg recombinant interleukin-2 (IL-2) intravenously (IV) every 4 hours separated by 1 week. This dose and schedule of IL-2 were identical to those u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efbde53a5374a00a4001dd14ef7fd2c4
https://doi.org/10.1200/jco.1990.8.10.1650

Zobrazit plný text záznamu

Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck

Autor: M, Suntharalingam, M L, Haas, D A, Van Echo, R, Haddad, M C, Jacobs, S, Levy, W C, Gray, R A, Ord, B A, Conley

Publikováno v: Cancer. 91(3)

The objective of this study was to determine prognostic factors for response and survival on three consecutive institutional trials utilizing concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck (SC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9f013fd93d86501e96477d1ec1a678ab
https://pubmed.ncbi.nlm.nih.gov/11169937

Zobrazit plný text záznamu

Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma

Autor: S H, Park, W C, Gray, I, Hernandez, M, Jacobs, R A, Ord, M, Sutharalingam, R G, Smith, D A, Van Echo, S, Wu, B A, Conley

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(3)

Although retinoids show promise for prevention of second primary upper aerodigestive tract tumors, the optimum retinoid, dose, and schedule are unknown. All-trans retinoic acid (ATRA) has greater affinity for retinoic acid receptors and may be more a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dcb119e887a531138133a6580fd82724
https://pubmed.ncbi.nlm.nih.gov/10741706

Zobrazit plný text záznamu

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors

Autor: B A, Conley, M J, Egorin, N, Tait, D M, Rosen, E A, Sausville, G, Dover, R J, Fram, D A, Van Echo

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 4(3)

Butyrates have been studied as cancer differentiation agents in vitro and as a treatment for hemoglobinopathies. Tributyrin, a triglyceride with butyrate molecules esterified at the 1, 2, and 3 positions, induces differentiation and/or growth inhibit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b2e42c324178f52b94aa9edca9afefad
https://pubmed.ncbi.nlm.nih.gov/9533530

Zobrazit plný text záznamu

Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone

Autor: Ritesh Patil, Jarrod P. Holmes, Sathibalan Ponniah, M. G. Carmichael, George E. Peoples, Guy T. Clifton, Nathan M. Shumway, Elizabeth A. Mittendorf, Alan K. Sears, D. C. Van Echo

Publikováno v: Journal of Clinical Oncology. 29:564-564

564 Background: We are conducting multiple, prospective, phase II trials evaluating different HER-2/neu(HER2) peptide vaccines in the adjuvant setting to prevent breast cancer (BrCa) recurrence. E75 (HER2: 369-377) and another vaccine (X) are HLA-A2/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::73b483f2e413cfeb5dcec76ccbf82dc9
https://doi.org/10.1200/jco.2011.29.15_suppl.564

Zobrazit plný text záznamu

Monitoring of circulating tumor cell trends in a prospective, randomized, placebo-controlled HER2/neu peptide vaccine trial

Autor: Guy T. Clifton, Nathan M. Shumway, George E. Peoples, Alan K. Sears, Jarrod P. Holmes, M. G. Carmichael, G. A. Merrill, D. C. Van Echo, Elizabeth A. Mittendorf, Ritesh Patil, S. McCall, Sathibalan Ponniah

Publikováno v: Journal of Clinical Oncology. 29:e11126-e11126

e11126 Background: Circulating tumor cells (CTC) may have a role as a prognostic marker and in monitoring therapeutic response in breast cancer (BrCa) patients. We are conducting a prospective, ran...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::054a7791f806149ee2876e5ae78b8eac
https://doi.org/10.1200/jco.2011.29.15_suppl.e11126

Zobrazit plný text záznamu

Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B

Autor: M. Goutsou, Kathleen J. Propert, S. Difino, M. C. Perry, M. R. Green, C. R. Modeas, D. A. Van Echo, E. D. Mitchell, Sharon D Luikart, J. O'Donnell

Publikováno v: American journal of clinical oncology. 16(2)

Previously untreated extensive small-cell lung cancer (SCLC) patients with performance status 0-2 were treated with etoposide 200 mg/m2/day on days 1-3 and carboplatin doses of 50, 100, or 125 mg/m2/day on days 1-3 in a Phase I format. Among the ten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55f93fc6a113d0f09840e130c78241b0
https://pubmed.ncbi.nlm.nih.gov/8383914

Zobrazit plný text záznamu

A predictive test for therapeutic treatment outcomes of advanced gastrointestinal cancer patients (AGC)

Autor: Naimish Pandya, M. Tan, Stephen A. Lesko, Nancy Tait, Katherine R. Tkaczuk, D. A. Van Echo, M. J. Sutula, S. Deamond, Paul O. P. Ts'o, Olga B. Ioffe

Publikováno v: Journal of Clinical Oncology. 27:e15079-e15079

e15079 Background: There are currently limited options for selecting an optimal treatment regimen for AGC patients. The Drug Response Indicator Test (DRIT) is a platform technology that provides a detailed profile of a patient's tumor response to com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff4622afbe57e2e902266a385b945215
https://doi.org/10.1200/jco.2009.27.15_suppl.e15079

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání